[1]
|
A. M. Wnuk, “Liver damage in HIV-infected patients,” Medical Science Monitor, vol. 7 , no. 4, pp. 729-236, 2001.
|
[2]
|
D. T. Dieterich, P. A. Robinson, J. Love and J. O. Stern, “Drug induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors,” Clinical Infectious Diseases, vol. 38, no. 2, p. S80–S89, 2004.
|
[3]
|
I. Bica, B. McGovern and R. Dhar, “Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection,” Clinical Infectious Diseases, vol. 32, no. 3, p. 492–497, 2001.
|
[4]
|
L. Mart´ ın-Carbonero, V. Soriano, E. Valencia, J. Garc´ ıaSamaniego, M. Lopez and J. Gonz ´ alez-Lahoz, “Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients,” AIDS Research and Human Retroviruses, vol. 17 , no. 16, p. 1467–1471, 2001.
|
[5]
|
M. S. Cappell, “Hepatobiliary manifestations of the acquired immune deficiency syndrome,” The American Journal of Gastroenterology, vol. 86, no. 1, pp. 1-15, 1991.
|
[6]
|
J. H. Lefkowitch, “Pathology of AIDS-related liver disease,” Digestive Diseases , vol. 12 , no. 6, p. 321–330, 1994.
|
[7]
|
C. Castellares, P. Barreiro and L. Mart´ ın-Carbonero, “Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome,” Journal of Viral Hepatitis, vol. 15, no. 3, p. 165–172, 2008.
|
[8]
|
N. Bodsworth, B. Donovan and B. N. Nightingale, “The effect of concurrent human imniunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men,” Journal of Infectious Diseases, vol. 160, no. 4, p. 577–582, 1989.
|
[9]
|
R. J. C. Gilson, A. E. Hawkins and M. R. Beecham, “Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection,” AIDS, vol. 11 , no. 5, p. 597–606, 1997.
|
[10]
|
E. Kenny-Walsh, “Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin,” The New England Journal of Medicine, vol. 340, no. 16, p. 1228–1233, 1999.
|
[11]
|
M. S. Sulkowski, D. L. Thomas, S. H. Mehta, R. E. Chaisson and R. D. Moore, “Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections,” Hepatology, vol. 35 , no. 1, p. 182–189, 2002.
|
[12]
|
H. Kovari, B. Ledergerber and M. Battegay, “Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus coinfection,” Clinical Infectious Diseases, vol. 50, no. 4, p. 502–511, 2010.
|
[13]
|
F. W. Wit, G. J. Weverling, J. Weel, S. Jurriaans and J. M. A. Lange, “Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy,” Journal of Infectious Diseases, vol. 186, no. 1, p. 23–31, 2002.
|
[14]
|
L. Aranzabal, J. L. Casado and J. Moya, “Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection,” Clinical Infectious Diseases, vol. 40, no. 4, p. 588–593, 2005.
|
[15]
|
US Department of Health and Human Services, Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, 2017.
|
[16]
|
S. Pol, P. Lebray and A. Vallet-Pichard, “HIV infection and hepatic enzyme abnormalities: Intricacies of the pathogenic mechanisms,” Clin Infect Dis, vol. 38, no. 2, p. S65–72, 2004.
|
[17]
|
T. Carlo, L. Giuseppe, C. Salvatore, P. Massimo, N. Mark and Q. Eugenia, “Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients; results from the Italian EPOKA-Master Cohort.,” BMC Inf Dis, 2005.
|
[18]
|
C. Burtis, E. Ashwood and D. Bruns, Tietz textbook of clinical chemistry and molecular diagnosis, Philadelphia: Elsevier Saunders Co, 2006.
|
[19]
|
G. Marc, H. Jay, S. Fauci, E. Braunwald, L. Kasper, L. Hauser, L. Longo, L. Jameson and J. Loscalzo, Harrison’s principles of internal medicine, 17 ed., New York: McGraw-Hill Companies, 2008, p. 1918–2000.
|
[20]
|
L. Hernandez, I. Gilson, J. Jacobson, A. Af, T. Puetz and V. Dindzans, “Antiretroviral hepatotoxicity in human immunodefciency virus-infected patients,” Aliment Pharmacol Ther, vol. 15, no. 10, p. 1627–32, 2001.
|
[21]
|
C. Hofmann, S. Charalambous, C. Thio, D. Martin, L. Pemb and K. Fielding, “Hepatotoxicity in an African antiretroviral therapy cohort: the efect of tuberculosis and hepatitis B,” AIDS, vol. 21, no. 10, p. 1301–8, 2007.
|
[22]
|
E. Tesfa, D. Siefu, Y. Belayneh and Z. Mekonnen, “Liver enzyme elevation in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital: a comparative cross-sectional study, Northeast Ethiopia,” BMC research notes, vol. 12, no. 714, 2019.
|
[23]
|
M. B. Shiferaw, K. T. Tulu, A. M. Zegeye and A. A. Wubante, “Liver Enzymes Abnormalities among Highly Active Antiretroviral Therapy Experienced and HAART Naive HIV-1 Infected Patients at Debre Tabor Hospital, North West Ethiopia: A Comparative Cross-Sectional Study,” AIDS Research and Treatment, 2016.
|
[24]
|
K. Lucent, A. Clement, N. Fon, P. Weldeji and C. Ndikvu, “The effects of antiretroviral treatment on liver function enzymes among HIV infected out patients attending the central hospital of Yaounde Cameron,” African Journal of Clinical and Experimental Microbiology, vol. 11, no. 3, p. 174–178, 2010.
|
[25]
|
A. C. M. Gil, R. Lorenzetti and G. B. Mendes, “Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy,” Sao Paulo Medical Journal, vol. 125, no. 4, p. 205–209, 2007.
|
[26]
|
S. Hussaini and E. Farrington, “Idiosyncratic drug-induced liver injury; an overview,” Expert Opin Drug Saf, vol. 6, no. 6, p. 673–84, 2007.
|
[27]
|
G. Yimer, W. Amogne, A. Habtewold, E. Makonnen, N. Ueda and A. Suda, “High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia; a prospective cohort study,” Pharmacogenomics J., vol. 12, no. 6, p. 499–506, 2012.
|
[28]
|
P. Ocama, B. Castelnuovo and M. Kamya, “Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda,” Int J STD AIDS, vol. 21, no. 8, p. 553–557, 2010.
|
[29]
|
T. Chalermchai, N. Hiransuthikul, P. Tangkijvanich, S. Pinyakorn, A. Avihingsanon and J. Ananworanich, “Risk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infection,” AIDS Research and Therapy, vol. 10, no. 1, 2013.
|
[30]
|
W. R. Kim, J. T. Benson, T. M. Therneau, H. A. Torgerson, B. P. Yawn and L. J. Melton III, “Changing epidemiology of hepatitis B in a U.S. Community,” Hepatology, vol. 39, no. 3, p. 811–816, 2004.
|
[31]
|
G. Guaraldi, N. Squillace and C. Stentarelli, “Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors,” Clinical Infectious Diseases, vol. 47 , no. 2, p. 250–257 , 2008.
|
[32]
|
M. Pokorska-Śpiewak, A. Stańska-Perka, J. Popielska, A. Ołdakowska and U. Coupland, “Prevalence and predictors of liver disease in HIV-infected children and adolescents,” Scientific Reports.
|
[33]
|
M. S. Pathania, S. L. N. Kaur, M. S. Kumar, A. C. V. Sashindran and B. P. Puri, “A cross-sectional study of liver function tests in HIV-infected persons in Western India,” medical journal armed forces india , vol. 73, p. 23–28, 2017 .
|
[34]
|
A. Rose, O. Abraham, J. Bode and N. Abel, “Risk factors for hepatotoxicity after introduction of highly active antiretroviral therapy,” E&C Hepatol, vol. 7, no. 1-2, p. 49–56, 2011 .
|
[35]
|
M. Ahmed, “Abacavir induced reversible fanconi syndrome with nephrogenic diabetes insipidus in patients with acquired immunodeficiency syndrome,” J Postgrad Med, vol. 52, no. 4, p. 296–297, 2006.
|
[36]
|
M. Krishnan, R. Nair, M. Haas and M. Atta, “Acute renal failure in HIV positive 50 year old man,” Am J Kidney Dis., vol. 36, no. 5, p. 1072–1078, 2000 .
|
[37]
|
WHO, “Clinical guidelines: Antiretroviral therapy,” in Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, Geneva, World Health Organization, 2017.
|